Leukemia Research
Volume 28, Issue 12 , Pages 1357-1361 , December 2004

Complex cytogenetics in a case of probably work related MDS/AML

Received 20 November 2003 ,Accepted 7 April 2004.

References 

  1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  2. Nisse C, Haguenoer LM, Grandbastein B, Preudhomme C, Fontaine B, et al.  Occupational and environmental risk factors of the myelodysplastic syndromes in the north of France. Br J Haematol. 2001;112:927–935
  3. Skov T, Maarup B, Olsen J, Rorth M, Winthereik H, et al.  Leukemia end reproductive outcome among nurses handling antineoplastic drugs. Br J Ind. Med. 1992;49:855–861
  4. McLaughlin JK. Formaldehyde and cancer: a critical review. Inter Arch. Occup. Health. 1994;66:295–301
  5. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov K. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood. 2002;99:1909–1912
  6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302
  7. Mitelman F, editor. ISCN: an international system for human cytogenetic nomenclature, Basel: S. Karger, 1995.
  8. Kakazu N, Taniwaki M, Horiike S, Nishida K, Tatekawa T, et al.  Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome. Genes Chromosomes Cancer. 1999;26:336–345
  9. Mrozek K, Heinonen K Theil KS, Bloomfield CD. Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent overrepresentation of 21q, 11q, and 22q. Genes Chromosomes Cancer. 2002;34:137–153
  10. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995;86:3542–3552
  11. Pedersen-Bjergaard J, Philip P. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood. 1991;78:1147–1148
  12. Larson RA, Le Beau MM, Ratain MJ, Rowley JD. Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia. Blood. 1992;79:1892–1893
  13. Dolan M, McGlennen RC, Hirsch B. MLL amplification in myeloid malignancies: clinical, molecular, and cytogenetic findings. Cancer Genet Cytogenet. 2002;134:93–101
  14. Andersen MK, Christiansen DH, Kirchhoff M, Pedersen-Bjergaard J. Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of TP53 gene and to previous therapy with alkylating agents. Genes Chromosomes Cancer. 2001;31:33–41
  15. Van Limbergen H, Poppe B, Michaux L, Herens C, Brown J, et al.  Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH. Genes Chromosomes Cancer. 2002;33:60–72

PII: S0145-2126(04)00128-6

doi: 10.1016/j.leukres.2004.04.005

Leukemia Research
Volume 28, Issue 12 , Pages 1357-1361 , December 2004

Article Tools

* Image Usage & Resolution